FDA Approves Abbott's Dual-Energy TactiFlex Duo Ablation Catheter for Complex Atrial Fibrillation
核心洞察
Abbott (搜索) has received US FDA approval for the TactiFlex Duo Ablation Catheter (搜索), Sensor Enabled, a dual-energy device for treating challenging cases of atrial fibrillation (搜索).
The catheter allows physicians to deliver pulsed field ablation, radiofrequency energy, or a combination of both during a single procedure to tailor treatment.
Approval was based on the FlexPulse IDE study, whose late-breaking data showed favorable safety and effectiveness outcomes in patients with paroxysmal AFib.
Abbott (搜索) has received US Food and Drug Administration (搜索) approval for the TactiFlex Duo Ablation Catheter (搜索), Sensor Enabled, a next-generation cardiac ablation device cleared to treat patients with challenging cases of atrial fibrillation (搜索) (AFib). The company said it will soon begin cases with broader commercial adoption across the country in the coming weeks.
The approval positions the dual-energy catheter as the latest addition to Abbott (搜索)'s electrophysiology portfolio, which the company describes as the industry's most comprehensive. AFib affects 10.5 million people in the United States who live with a heart that beats too fast, too slow or irregularly, and the arrhythmia increases the risk of serious complications including stroke. While many patients are managed with medications, others require cardiac ablation, a minimally invasive procedure that targets the tissue responsible for abnormal electrical signals in the heart.
Dual-Energy Design and Integrated Mapping
TactiFlex Duo allows physicians to use pulsed field ablation (PFA), radiofrequency (RF) energy, or a combination of both during a procedure, enabling treatment to be tailored to each patient's needs. The dual-energy approach is intended to create precise therapeutic lesions — small areas of scar tissue that block the abnormal electrical signals causing an irregular heartbeat — while helping minimize the impact on surrounding healthy tissue.
The catheter is integrated with Abbott (搜索)'s EnSite X EP System, a mapping platform that generates detailed three-dimensional maps of the heart to help physicians locate and treat the source of an irregular heartbeat. The system provides real-time feedback through the PFA Index (PI), a tool designed to assess lesion formation during ablation with TactiFlex Duo. Working alongside Abbott's Advisor HD Grid X mapping catheter, ViewFlex X ICE (intracardiac echocardiography) catheter and EnSite Echo Module, the integrated portfolio is designed to give physicians real-time images of the ablation catheter's positioning and movement, along with a digital model of the patient's heart throughout the procedure.
"Electrophysiology is rapidly evolving as physicians adopt new technologies that improve the safety and effectiveness of AFib treatment," said Atul Verma, M.D., director of cardiology at the McGill University Health Centre in Montreal, Canada, and a globally recognized expert in pulsed field ablation technology. "TactiFlex Duo provides physicians with greater flexibility during procedures, and when it is combined with the high-resolution 3D visualization available through Abbott (搜索)'s EnSite X mapping system, physicians have a suite of practice-changing tools to confidently treat patients with complex AFib."
FlexPulse IDE Data Supported the Approval
The FDA approval was secured based on results from Abbott (搜索)'s FlexPulse IDE study. Late-breaking data from the study, recently presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in EP Europace, showed favorable safety and effectiveness outcomes in patients with paroxysmal AFib — irregular heart rhythm episodes that come and go. Abbott said clinical data has shown the technology to be safe and effective.
Patients with atrial fibrillation (搜索), particularly those with complex anatomy, prior or failed ablations, or other challenging clinical situations, may benefit from treatment with TactiFlex Duo as determined by their physician.
"TactiFlex Duo represents an important advancement as Abbott (搜索) builds the industry's most comprehensive electrophysiology portfolio," said Uri Yaron, senior vice president of Abbott's electrophysiology business. "From diagnosis, mapping and intracardiac ultrasound imaging to advanced treatments for the most complex arrhythmias, Abbott is uniquely positioned to support physicians at every stage of patient care. By continuing to expand our PFA portfolio and integrate innovative technologies across cardiovascular care, we're helping physicians navigate increasingly complex procedures while ensuring more patients receive the right care at the right time."
Fifth Electrophysiology Approval in Just Over a Year
The US clearance further expands Abbott (搜索)'s portfolio of technologies for treating cardiac arrhythmias and represents the company's fifth major electrophysiology approval in just over a year. It follows Europe's Amulet 360 (搜索) and TactiFlex Duo CE Mark approvals this year, as well as US and European approvals of the Volt PFA System (搜索) in 2025.
The approval arrives amid rapid growth in the electrophysiology segment. In the second quarter of 2026, Abbott (搜索)'s electrophysiology sales grew 13.4% year over year. According to a report by Research Nester cited in analyst coverage, the cardiac ablation market was valued at $5.50 billion in 2025 and is projected to exceed $17.86 billion by 2035, registering a compound annual growth rate of more than 12.5% during the 2026–2035 forecast period; the market is estimated at $6.12 billion in 2026.
Following the announcement, Abbott (搜索)'s shares edged down 2.6% to close at $105.52. The company has a market capitalization of $187.45 billion and an earnings yield of 5.1%, compared with the industry's 2.5%, and delivered an average earnings surprise of 0.8% over the trailing four quarters.